While several studies have reported reduced expression of ADAMTS5 in cancers, such as prostate cancer [7], breast cancer [8], colorectal cancer [9], and hepatocellular carcinoma (HCC) [10], others have reported elevated expression of ADAMTS5 in human glioblastomas [11]. Here, ADAMTS5 is linked to prostate carcinoma.